





To the Editor: Bartonella hense-
lae is the causative agent of cat-scratch 
disease, which is the most common 
form of human bartonellosis (1). In 
immunocompromised patients, e.g., 
HIV-infected patients, B. henselae can 
give rise to longstanding fever, bacil-
lary angiomatosis, and peliosis hepati-
tis (2). Domestic cats are the reservoir 
for B. henselae, and cat ﬂ  eas transmit 
the organism between cats (3). The 
seroprevalence and culture ﬁ  ndings 
of Bartonella spp. in cats have been 
shown to be low in Sweden (4,5) 
compared with warmer areas (6). Cat-
scratch disease is most often spread 
from cats to humans by scratches, but 
other forms of transmission, including 
cat bites, have been suggested (7).
To determine seroprevalence 
of antibodies against B. henselae in 
Sweden, we used data from a recently 
published prospective study of pa-
tients with infected cat bites (8). In ad-
dition to the information about bites, 
information about cat scratches was 
collected by retrospective review of 
the patients’ medical records. Serum 
samples were taken during the pa-
tient’s ﬁ  rst visit to a hospital and at 
a follow-up visit about 2 weeks later. 
The study was approved by the local 
ethics committee. 
Immunoglobulin G against spe-
ciﬁ  c Bartonella spp. was detected by 
the immunoﬂ  uorescence antibody test 
(1). Cell-cultivated antigens were pre-
pared from the following strains: B. 
henselae Houston-1 (ATCC 49882), 
B. henselae Marseille (CIP 104756), 
B. henselae Berlin1 (M. Arvand), B. 
henselae K68 (E. Olsson-Engvall), 
B. elizabethae (ATCC 49927), and B. 
grahamii (ATCC 700132). The cutoff 
values for a positive immunoﬂ  uores-
cence antibody test result were chosen 
as >128 for B. henselae and B. graha-
mii and >256 for B. elizabethae. The 
titers are expressed as the reciprocal of 
the end-point dilution. For controls, we 
also analyzed serum from 117 blood 
donors with these antigens. The χ2 test 
was used for statistical analysis.
We analyzed antibodies to Barto-
nella spp. in serum from 71 patients 
(51 women and 20 men), median age 
47 years (range 15–85 years). Only 11 
patients had fever. Cat scratches were 
reported for 17 patients. A single se-
rum sample was obtained from 37 of 
the 71 patients, and an additional con-
valescent-phase sample was obtained 
from 34 patients after a median of 16 
days (range 6–54 days).
Antibodies against any B. hense-
lae strain were found for 24/71 (34%) 
patients, against B. elizabethae for 
9/71 (13%), and against B. graha-
mii for 12/71 (17%). A total of 13/71 
(18%) patients showed reactivity to 
B. henselae only. Antibodies to any 
Bartonella spp. were found for 28/71 
(39%) of the patients. As many as 
13/24 (54%) serum samples with an-
tibodies against B. henselae reacted 
to antigens of only that species. More 
patients (19/71; 27%) reacted to the 
antigen from the cat in Sweden, K68, 
than to other strains. The least com-
mon reactivity found in this study 
was against the B. henselae Marseille 
strain.
Of the 117 controls, 1 (0.8%) had 
antibodies against B. henselae K68 
antigens, 3 (2.6%) against Berlin1, 
2 (1.7%) against Marseille, 1 (0.8%) 
against Houston-1, and 4 (3.4%) 
against any Bartonella spp. The dif-
ference between patients and controls 
was signiﬁ  cant (p<0.001).
Seroconversion was reported for 6 
of the 34 patients (18%) from which 2 
serum samples were analyzed (Table). 
Among those who seroconverted for 
B. henselae, 1 had fever and only 2 re-
ported having been scratched. Two of 
the patients who seroconverted were 
treated with doxycycline, and 1 was 
treated with ciproﬂ  oxacin. In addition, 
1 patient with Sjogren disease was ini-
tially treated with penicillin, and later 
a hemangioma-like exanthema de-
veloped. Because of severe acne, the 
patient was treated with doxycycline 
for 6 months. The other patients who 
seroconverted were treated with peni-
cillin or amoxicillin.
Seroconversion for B. henselae 
occurred in 4 patients, of which only 2 
had reported a scratch. Three of these 
patients reacted to B. henselae Ber-
lin1, and 1 reacted to the Houston-1 
strain. Because symptoms did not dif-
fer between the patients who did sero-
convert and those who did not, these 
ﬁ  ndings could indicate subclinical in-
fection.
The prevalence of immunoglobu-
lin G against B. henselae in particular 
was shown to be much higher than 
that previously reported in Swe-
den (9). Earlier studies used only 2 
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Table. Titers against Bartonella spp. antigens in 6 patients who seroconverted 
Reciprocal titer  Patient sex/ 
age, y  Acute-phase serum  Convalescent-phase serum  Interval, d  Antigen
High titer 
to other antigen 
F/77 32 128 6 B. henselae Berlin1 B. henselae K68
F/50 32 256 17 B. henselae Berlin1 0
M/74 128 512 19 B. grahamii B. henselae K68
F/62 32 128 44 B. elizabethae B. henselae K68
M/56 32 128 15 B. henselae Houston-1  B. grahamii
F/23 32 128 10 B. henselae Berlin1 B. grahamii
1Presented in part at the 4th International 
Conference on Bartonella as Emerging 
Pathogens, 2004 Aug 26–28, Uppsala, 
Sweden. LETTERS
B. henselae antigens (Houston-1 and 
Marseille) compared with the 4 dif-
ferent  B. henselae antigens used in 
the present study. Most reactivity to 
B. henselae in the present study was 
directed against the Swedish isolate 
K68 (27%); only 0.8% of controls had 
antibodies against that antigen.
An increased prevalence of an-
tibodies against B. henselae after ex-
posure to cats has been reported from 
Spain (10). Because seroconversion 
against B. henselae occurred in 2 pa-
tients who had not been scratched, cat 
bites may contribute to transmission 
of B. henselae.
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To the Editor: Israeli spotted 
fever (ISF) is caused by Rickettsia 
conorii subsp. israelensis. This recent-
ly described subspecies is genetically 
close to R. conorii subsp. conorii, the 
agent of Mediterranean spotted fever 
(MSF) (1,2). ISF is likely transmitted 
by the dog tick Rhipicephalus san-
guineus (3). This tick, which is also the 
vector of R. conorii subsp. conorii, has 
low afﬁ  nity for hosts other than dogs. 
Therefore, like MSF, cases of ISF will 
likely be sporadic (4,5). ISF was ﬁ  rst 
reported in Israel (1) and was also re-
cently described in Portugal and Italy 
(6–8). The clinical manifestations of 
ISF are similar to those of other spot-
ted fever group infections, but an in-
oculation eschar is rarely observed and 
a history of tick exposure is not always 
present (4–6,9). The incubation period 
is ≈7–8 days after the tick bite (4).
We describe a 63-year-old man 
who had fatal ISF despite adequate 
therapy. The patient, who lived in 
Switzerland, took a cruise on the 
Mediterranean Sea, sailing for a week 
along the coasts of Crete, Libya, and 
Malta (Figure). With his wife, he visit-
ed several archeological sites in Libya 
(Cyrene, Apollonia, Ptolemais, Leptis 
Magna, Sabratha). Three days after 
returning to Switzerland, the patient 
reported loss of appetite, epigastric 
pain, and loose stools. Four days later, 
a fever (40°C) and generalized rash de-
veloped. The patient was hospitalized 
6 days after symptom onset. At that 
time, he had fever (38.3°C), hypoten-
sion (85/55 mm Hg), tachycardia (100/
min); a maculopapular rash involving 
the trunk, limbs, palms, and soles; and 
petechial lesions on the right arm. The 
patient was confused and exhibited bi-
lateral dysdiadochokinesis. Laboratory 
investigations yielded the following 
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Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words 
and 10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.